세계의 고콜레스테롤혈증 시장 보고서(2025년)

Hypercholesterolemia Global Market Report 2025

US $ 4,490 ￦ 6,151,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 8,891,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,632,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

고콜레스테롤혈증 시장 규모는 향후 수년간 급성장이 전망될 예정입니다. 콜레스테롤 관련 리스크에 대한 의식의 고조 등의 요인에 의한 것으로 예측됩니다. 지방 동향으로는 지질 프로파일링의 진보, 로봇 지원 수술의 이용, 드러그 딜리버리에 있어서의 나노 테크놀로지의 응용, 원격 의료 플랫폼의 대두, 리포단백 표적에 대한 주목 등을 들 수 있습니다.

심혈관 질환의 유병률 증가는 향후 수년간 고콜레스테롤혈증 시장의 성장을 가속할 것으로 예측됩니다. 심혈관 질환의 증가는 주로 건강에 해로운 식단, 신체 활동 부족, 비만율 증가, 만성 스트레스, 인구 고령화, 고혈압 및 당뇨병과 같은 질환의 유병률에 기인합니다. 심장 마비, 뇌졸중 및 기타 심혈관 합병증의 위험을 줄임으로써 심혈관 질환 환자를 지원합니다. 2024년 10월에 미국 질병통제예방센터는 매년 약 805,000명이 심장마비를 경험하고 있으며 그 중 60만 5,000명이 처음 발생하는 사건이고, 20만명이 심장 마비 기왕력이 있는 사람입니다. 그 때문에 심혈관 질환의 이환율 증가는 고콜레스테롤혈증 시장을 촉진할 것으로 예측됩니다.

고콜레스테롤혈증 시장의 주요 진출기업은 치료 효과를 높이고 환자의 컴플라이언스를 향상시키기 위해 3제 병용약 등의 혁신적인 제품을 개발하고 있습니다. 삼중 결합 약물은 정제나 캡슐과 같은 세 가지 활성 성분을 단일 용량 형태로 결합한 것입니다. 예를 들면, 2025년 2월, 한국의 제약회사 셀트리온사가 고혈압 및 고지혈증 치료제인 암로제트 정제를 출시했습니다. 이 약물은 고혈압의 칼슘 채널 차단제인 암로디핀, 콜레스테롤을 낮추는 스타틴인 로수바스타틴, 장내 콜레스테롤 흡수를 줄이는 데 도움이 되는 에제티미브 등 세 가지 활성 성분을 결합한 것입니다. 이 약물은 네 가지 용량 조합(5/5/10 mg, 5/10/10 mg, 10/5/10 mg, 10/10 mg)으로 제공되며, 암로디핀 투여 시 고혈압 및 심근 허혈, 로수바스타틴-에제티미브 병용 시 일차성 고콜레스테롤혈증, 만성 안정 협심증 또는 혈관성 협심증 완화에도 사용됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 고콜레스테롤혈증 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 고콜레스테롤혈증 시장 : 성장률 분석
• 세계의 고콜레스테롤혈증 시장 실적 : 규모와 성장, 2019-2024년
• 세계의 고콜레스테롤혈증 시장 예측 : 규모와 성장, 2024-2029년, 2034년
• 세계의 고콜레스테롤혈증 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 고콜레스테롤혈증 시장 : 질환 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 유전성
• 후천성
• 세계의 고콜레스테롤혈증 시장 : 치료별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 스타틴
• 담즙산 수지
• 니아신
• PCSK9 억제제
• 콜레스테롤 흡수 억제제
• 피브린산 유도체
• 기타
• 세계의 고콜레스테롤혈증 시장 : 투여 경로별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 경구
• 주사제
• 세계의 고콜레스테롤혈증 시장 : 유통 채널별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 병원 약국
• 소매 약국
• 기타 유통 채널
• 세계의 고콜레스테롤혈증 시장 : 최종 사용자별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 병원
• 전문 클리닉
• 재택 헬스케어
• 기타
• 세계의 고콜레스테롤혈증 시장 : 유전성별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 헤테로접합성 가족성 고콜레스테롤혈증
• 호모접합성 가족성 고콜레스테롤혈증
• 세계의 고콜레스테롤혈증 시장 : 후천성별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 1차 고콜레스테롤혈증
• 2차 고콜레스테롤혈증

제7장 지역별/국가별 분석

• 세계의 고콜레스테롤혈증 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 세계의 고콜레스테롤혈증 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 고콜레스테롤혈증 시장 : 경쟁 구도
• 고콜레스테롤혈증 시장 : 기업 프로파일
  • Pfizer Inc.
  • Merck & Co Inc.
  • Abbvie Inc.
  • Bayer AG
  • Sanofi SA

제31장 기타 주요 기업 및 혁신 기업

• AstraZeneca PLC
• Novartis AG
• GlaxoSmithKline plc(GSK)
• Eli Lilly and Company
• Amgen Inc.
• Viatris Inc.
• Aegerion Pharmaceuticals Inc.
• Fresenius Kabi AG
• Sun Pharmaceutical Industries Ltd.
• Chiesi Farmaceutici SpA
• Aurobindo Pharma Limited
• Dr. Reddy's Laboratories Ltd.
• Lupin Limited
• Ionis Pharmaceuticals Inc.
• Melinta Therapeutics Inc.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

• 고콜레스테롤혈증 시장, 2029년 : 새로운 기회를 제공하는 국가
• 고콜레스테롤혈증 시장, 2029년 : 새로운 기회를 제공하는 부문
• 고콜레스테롤혈증 시장, 2029년 : 성장 전략
  • 시장 동향에 의한 전략
  • 경쟁 전략

제36장 부록

SHW

영문 목차

영문목차

Hypercholesterolemia refers to an abnormally high level of cholesterol in the blood, particularly low-density lipoprotein (LDL) cholesterol, which increases the risk of atherosclerosis and cardiovascular diseases such as heart attacks and strokes. It is often influenced by genetic factors, poor diet, lack of physical activity, and underlying health conditions such as diabetes or hypothyroidism.

The primary types of hypercholesterolemia are genetic and acquired. Genetics refers to the study of genes, heredity, and the variation of inherited traits in living organisms, which play a crucial role in determining susceptibility to various conditions, including familial hypercholesterolemia. Treatment for hypercholesterolemia includes statins, bile acid resins, niacin, PCSK9 inhibitors, cholesterol absorption inhibitors, fibric acid derivatives, and other medications. These treatments are available in oral and injectable forms. They are distributed through various channels, such as hospital pharmacies, retail pharmacies, and other outlets, and are used by a wide range of end users, including hospitals, specialty clinics, home healthcare providers, and others.

The hypercholesterolemia market research report is one of a series of new reports from The Business Research Company that provides hypercholesterolemia market statistics, including hypercholesterolemia industry global market size, regional shares, competitors with a hypercholesterolemia market share, detailed hypercholesterolemia market segments, market trends and opportunities, and any further data you may need to thrive in the hypercholesterolemia industry. This hypercholesterolemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hypercholesterolemia market size has grown rapidly in recent years. It will grow from $16.30 billion in 2024 to $18.66 billion in 2025 at a compound annual growth rate (CAGR) of 14.5%. The growth during the historic period can be attributed to several factors, including the rise of health campaigns, increased investment in research and development, a growing emphasis on preventive healthcare, and the expansion of preventive health screenings alongside lifestyle modifications.

The hypercholesterolemia market size is expected to see rapid growth in the next few years. It will grow to $31.70 billion in 2029 at a compound annual growth rate (CAGR) of 14.2%. The growth during the forecast period can be attributed to factors such as improved diagnosis and screening, government initiatives and health policies, the growing prevalence of risk factors, the increasing availability of over-the-counter (OTC) cholesterol-lowering products, and heightened awareness of cholesterol-related risks. Key trends include advancements in lipid profiling, the use of robotic-assisted surgeries, the application of nanotechnology in drug delivery, the rise of telemedicine platforms, and the focus on lipoprotein targeting.

The growing prevalence of cardiovascular diseases is expected to drive the growth of the hypercholesterolemia market in the coming years. Cardiovascular diseases (CVDs) are a group of disorders affecting the heart and blood vessels. The rise in cardiovascular diseases is largely due to unhealthy diets, physical inactivity, increasing obesity rates, chronic stress, aging populations, and the prevalence of conditions such as hypertension and diabetes. Hypercholesterolemia treatments help cardiovascular disease patients by lowering LDL cholesterol levels, reducing plaque buildup in the arteries, improving blood flow, and decreasing the risk of heart attacks, strokes, and other cardiovascular complications. For instance, in October 2024, the Centers for Disease Control and Prevention reported that around 805,000 people in the United States experience a heart attack each year, with 605,000 being first-time incidents and 200,000 occurring in individuals with a history of previous heart attacks. Therefore, the rising incidence of cardiovascular diseases is expected to propel the hypercholesterolemia market.

Key players in the hypercholesterolemia market are developing innovative products, such as triple-combination drugs, to improve treatment efficacy and enhance patient compliance. A triple-combination drug combines three active ingredients into a single dosage form, such as a tablet or capsule. For example, in February 2025, Celltrion Pharm, Inc., a South Korea-based pharmaceutical company, launched Amrozet Tablet, a drug for hypertension and hyperlipidemia. This medication combines three active ingredients such as amlodipine, a calcium channel blocker for hypertension; rosuvastatin, a statin to lower cholesterol; and ezetimibe, which helps reduce cholesterol absorption in the intestines. The drug is available in four dosage combinations (5/5/10 mg, 5/10/10 mg, 10/5/10 mg, and 10/10/10 mg) and is indicated for hypertension and myocardial ischemia under amlodipine, primary hypercholesterolemia under the rosuvastatin-ezetimibe combination, and also for relieving chronic stable angina or vasospastic angina. Additionally, it helps reduce the risk of hospitalization for angina and heart surgery in patients with documented coronary artery disease.

In August 2023, HDL Therapeutics, Inc., a U.S.-based biotechnology company, merged with Swiftmerge Acquisition Corp. for an undisclosed amount. This merger aims to accelerate the commercialization of HDL Therapeutics' FDA-approved Plasma Delipidation System (PDS-2) for treating patients with homozygous familial hypercholesterolemia (HoFH). Swiftmerge Acquisition Corp. is a U.S.-based special purpose acquisition company (SPAC) focused on providing treatment for HoFH.

Major players in the hypercholesterolemia market are Pfizer Inc., Merck & Co Inc., Abbvie Inc., Bayer AG, Sanofi S.A., AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Amgen Inc., Viatris Inc., Aegerion Pharmaceuticals Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Lupin Limited, Ionis Pharmaceuticals Inc., Melinta Therapeutics Inc., NewAmsterdam Pharma N.V., HDL Therapeutics Inc.

North America was the largest region in the hypercholesterolemia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hypercholesterolemia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hypercholesterolemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hypercholesterolemia market consists of sales of omega-3 fatty acid supplements, atorvastatin, and simvastatin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hypercholesterolemia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hypercholesterolemia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hypercholesterolemia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hypercholesterolemia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Genetic; Acquired
• 2) By Treatment: Statins; Bile Acid Resins; Niacin; PCSK9 Inhibitors; Cholesterol Absorption Inhibitors; Fibric Acid Derivatives; Other Treatments
• 3) By Route Of Administration: Oral; Injectable
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Others Distribution Channel
• 5) By End User: Hospitals; Specialty Clinics; Home Healthcare; Others End Users
• Subsegments:
• 1) By Genetic: Heterozygous Familial Hypercholesterolemia; Homozygous Familial Hypercholesterolemia
• 2) By Acquired: Primary Hypercholesterolemia; Secondary Hypercholesterolemia
• Companies Mentioned: Pfizer Inc.; Merck & Co Inc.; Abbvie Inc.; Bayer AG; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hypercholesterolemia Market Characteristics

3. Hypercholesterolemia Market Trends And Strategies

4. Hypercholesterolemia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Hypercholesterolemia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hypercholesterolemia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hypercholesterolemia Market Growth Rate Analysis
• 5.4. Global Hypercholesterolemia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hypercholesterolemia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hypercholesterolemia Total Addressable Market (TAM)

6. Hypercholesterolemia Market Segmentation

• 6.1. Global Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Genetic
• Acquired
• 6.2. Global Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Statins
• Bile Acid Resins
• Niacin
• PCSK9 Inhibitors
• Cholesterol Absorption Inhibitors
• Fibric Acid Derivatives
• Other Treatments
• 6.3. Global Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• 6.4. Global Hypercholesterolemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Others Distribution Channel
• 6.5. Global Hypercholesterolemia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Home Healthcare
• Others End Users
• 6.6. Global Hypercholesterolemia Market, Sub-Segmentation Of Genetic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Heterozygous Familial Hypercholesterolemia
• Homozygous Familial Hypercholesterolemia
• 6.7. Global Hypercholesterolemia Market, Sub-Segmentation Of Acquired, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Primary Hypercholesterolemia
• Secondary Hypercholesterolemia

7. Hypercholesterolemia Market Regional And Country Analysis

• 7.1. Global Hypercholesterolemia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hypercholesterolemia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hypercholesterolemia Market

• 8.1. Asia-Pacific Hypercholesterolemia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hypercholesterolemia Market

• 9.1. China Hypercholesterolemia Market Overview
• 9.2. China Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hypercholesterolemia Market

• 10.1. India Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hypercholesterolemia Market

• 11.1. Japan Hypercholesterolemia Market Overview
• 11.2. Japan Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hypercholesterolemia Market

• 12.1. Australia Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hypercholesterolemia Market

• 13.1. Indonesia Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hypercholesterolemia Market

• 14.1. South Korea Hypercholesterolemia Market Overview
• 14.2. South Korea Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hypercholesterolemia Market

• 15.1. Western Europe Hypercholesterolemia Market Overview
• 15.2. Western Europe Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hypercholesterolemia Market

• 16.1. UK Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hypercholesterolemia Market

• 17.1. Germany Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hypercholesterolemia Market

• 18.1. France Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hypercholesterolemia Market

• 19.1. Italy Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hypercholesterolemia Market

• 20.1. Spain Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hypercholesterolemia Market

• 21.1. Eastern Europe Hypercholesterolemia Market Overview
• 21.2. Eastern Europe Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hypercholesterolemia Market

• 22.1. Russia Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hypercholesterolemia Market

• 23.1. North America Hypercholesterolemia Market Overview
• 23.2. North America Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hypercholesterolemia Market

• 24.1. USA Hypercholesterolemia Market Overview
• 24.2. USA Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hypercholesterolemia Market

• 25.1. Canada Hypercholesterolemia Market Overview
• 25.2. Canada Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hypercholesterolemia Market

• 26.1. South America Hypercholesterolemia Market Overview
• 26.2. South America Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hypercholesterolemia Market

• 27.1. Brazil Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hypercholesterolemia Market

• 28.1. Middle East Hypercholesterolemia Market Overview
• 28.2. Middle East Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hypercholesterolemia Market

• 29.1. Africa Hypercholesterolemia Market Overview
• 29.2. Africa Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hypercholesterolemia Market Competitive Landscape And Company Profiles

• 30.1. Hypercholesterolemia Market Competitive Landscape
• 30.2. Hypercholesterolemia Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Hypercholesterolemia Market Other Major And Innovative Companies

• 31.1. AstraZeneca PLC
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline plc (GSK)
• 31.4. Eli Lilly and Company
• 31.5. Amgen Inc.
• 31.6. Viatris Inc.
• 31.7. Aegerion Pharmaceuticals Inc.
• 31.8. Fresenius Kabi AG
• 31.9. Sun Pharmaceutical Industries Ltd.
• 31.10. Chiesi Farmaceutici S.p.A.
• 31.11. Aurobindo Pharma Limited
• 31.12. Dr. Reddy's Laboratories Ltd.
• 31.13. Lupin Limited
• 31.14. Ionis Pharmaceuticals Inc.
• 31.15. Melinta Therapeutics Inc.

32. Global Hypercholesterolemia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hypercholesterolemia Market

34. Recent Developments In The Hypercholesterolemia Market

35. Hypercholesterolemia Market High Potential Countries, Segments and Strategies

• 35.1 Hypercholesterolemia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hypercholesterolemia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hypercholesterolemia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료